Research Analysts Offer Predictions for ESPR Q2 Earnings
Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report) – Research analysts at HC Wainwright lowered their Q2 2025 earnings per share (EPS) estimates for Esperion Therapeutics in a research report issued to clients and investors on Tuesday, May 6th. HC Wainwright analyst J. Pantginis now anticipates that the biopharmaceutical company will earn ($0.19) per share for […]
Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report) – Research analysts at HC Wainwright lowered their Q2 2025 earnings per share (EPS) estimates for Esperion Therapeutics in a research report issued to clients and investors on Tuesday, May 6th. HC Wainwright analyst J. Pantginis now anticipates that the biopharmaceutical company will earn ($0.19) per share for […]
